StoxVijaya Diagnostic Centre vs Concord Biotech: share price & financials comparison
NSE: VIJAYA vs CONCORDBIO · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Vijaya Diagnostic Centre vs Concord Biotech at a glance
Vijaya Diagnostic Centre (VIJAYA) has a market capitalisation of ₹15,126 Cr, against ₹6,618 Cr for Concord Biotech (CONCORDBIO). Over the past year Vijaya Diagnostic Centre has returned +45.8%, compared with -12.9% for Concord Biotech. On valuation, Concord Biotech trades at a lower P/E of 23.4 versus 74.3. Vijaya Diagnostic Centre earns a higher return on equity (19.3% vs 13.6%). Vijaya Diagnostic Centre comes out ahead on profitability, growth, momentum and technicals. Concord Biotech comes out ahead on size and valuation. Across the scored metrics below, Vijaya Diagnostic Centre leads on 10 and Concord Biotech on 5. On StoxGud's 10-point checklist, Vijaya Diagnostic Centre scores 9/10 and Concord Biotech scores 6/10.
| Metric | Vijaya Diagnostic Centre | Concord Biotech |
|---|---|---|
| Size | ||
| Market cap | ₹15,126 Cr | ₹6,618 Cr |
| Revenue (latest FY) | ₹814 Cr | ₹1,055 Cr |
| Net profit (latest FY) | ₹173 Cr | ₹261 Cr |
| Valuation | ||
| P/E | 74.3 | 23.4 |
| P/B | 14.31 | 3.19 |
| Dividend yield | 0.14% | 1.69% |
| Profitability | ||
| Return on equity | 19.3% | 13.6% |
| Net profit margin | 22.4% | 24.1% |
| Operating margin | 43.1% | 34.5% |
| Growth | ||
| Revenue growth (YoY) | +26.7% | +25.1% |
| Net profit growth (YoY) | +37.4% | +11.1% |
| Revenue CAGR (multi-year) | +15.2% | +1.8% |
| Financial health | ||
| Debt to equity | 0.00 | 0.00 |
| Momentum | ||
| 1-month return | +0.4% | -7.0% |
| 1-year return | +45.8% | -12.9% |
| 3-year CAGR | +35.9% | +3.6% |
| 5-year CAGR | +21.1% | — |
| Distance from 52W high | -6.5% | -20.3% |
| Technicals | ||
| RSI (14) | 67 | 45 |
| Price vs 200-day avg | +18.0% | -0.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Vijaya Diagnostic Centre | Concord Biotech |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Vijaya Diagnostic Centre or Concord Biotech?
Vijaya Diagnostic Centre has a market cap of ₹15,126 Cr and Concord Biotech has a market cap of ₹6,618 Cr as of 06 Nov 2026.
Which has a lower P/E, Vijaya Diagnostic Centre or Concord Biotech?
Concord Biotech has the lower P/E: Vijaya Diagnostic Centre trades at 74.3 and Concord Biotech at 23.4.
Which gave better returns in the last year, Vijaya Diagnostic Centre or Concord Biotech?
Vijaya Diagnostic Centre did better: Vijaya Diagnostic Centre returned +45.8% and Concord Biotech returned -12.9% over one year.
Is Vijaya Diagnostic Centre or Concord Biotech a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Vijaya Diagnostic Centre scores 9/10 and Concord Biotech scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.